Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | What financial challenges patients and healthcare systems face in oncology?

Daniel Goldstein • 23 Oct 2026
ESMO 2026
General

Daniel Goldstein, MD, Davidoff Center, Rabin Medical Center, Tel Aviv, Israel, discusses the issue of class effects in oncology and its potential opportunities for healthcare payers and systems. Dr Goldstein highlights the significant financial challenges faced by individual patients and healthcare systems as a whole, including the high costs of care, bankruptcy, and the increasing unsustainability of healthcare systems. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Daniel Goldstein

Drug price competition and the potential for tendering in oncology care
1:34
Drug price competition and the potential for tendering in oncology care
Daniel Goldstein • 23 Oct 2026
Assessing the interchangeability & dosage of checkpoint inhibitors
3:30
Assessing the interchangeability & dosage of checkpoint inhibitors
Daniel Goldstein • 31 Mar 2025
The economic benefits of reducing ICI dosage in cancer treatment
0:48
The economic benefits of reducing ICI dosage in cancer treatment
Daniel Goldstein • 31 Mar 2025
Evaluating the efficacy of lower-/shorter-course ICI regimens
1:02
Evaluating the efficacy of lower-/shorter-course ICI regimens
Daniel Goldstein • 31 Mar 2025

Related Videos

Drug price competition and the potential for tendering in oncology care
1:34
Drug price competition and the potential for tendering in oncology care
Daniel Goldstein • 23 Oct 2026
How can we enhance the efficacy of TILs therapy in solid tumors?
2:27
How can we enhance the efficacy of TILs therapy in solid tumors?
Paolo Ascierto • 23 Oct 2026
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
1:49
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
Paolo Ascierto • 23 Oct 2026
Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals